Last reviewed · How we verify
MR308
MR308 is a selective antagonist of the P2X3 receptor that reduces pain signaling in sensory neurons.
MR308 is a selective antagonist of the P2X3 receptor that reduces pain signaling in sensory neurons. Used for Chronic cough, Neuropathic pain.
At a glance
| Generic name | MR308 |
|---|---|
| Also known as | Tramadol/Celecoxib, Tramadol, Celecoxib, Placebos |
| Sponsor | Mundipharma Research GmbH & Co KG |
| Drug class | P2X3 receptor antagonist |
| Target | P2X3 |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | Phase 3 |
Mechanism of action
P2X3 receptors are ion channels expressed on nociceptive nerve fibers that mediate pain transmission when activated by extracellular ATP. By blocking P2X3, MR308 reduces the excitability of pain-sensing neurons and dampens pain signal propagation to the central nervous system. This mechanism is particularly relevant for chronic pain conditions where ATP-mediated signaling contributes to persistent pain states.
Approved indications
- Chronic cough
- Neuropathic pain
Common side effects
- Taste disturbance
- Dizziness
- Headache
Key clinical trials
- Efficacy and Safety in a Randomised Acute Pain Study of MR308: STARDOM2. (PHASE3)
- Efficacy and Safety in a Randomised Acute Pain Study of MR308 (Tramadol/Celecoxib). (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MR308 CI brief — competitive landscape report
- MR308 updates RSS · CI watch RSS
- Mundipharma Research GmbH & Co KG portfolio CI